This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E, or MMAE) to B-cells, which results in the killing of malignant B-cells. Polivy is approved for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma, and adult patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant.
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
M-PK-00001707
Solutions